A Comparative Study to Evaluate the Accuracy and Safety of the GlySure Continuous Intravascular Glucose Monitoring System Versus Intermittent Blood Glucose Monitoring

Inclusion criteria

• Patient or legal representative MUST be willing to sign an informed consent document
• Male and female aged 18 years and above
• Require Central Venous Catheter (CVC) into the right internal Jugular vein as part of disease management and treatment
• Expected to remain in the Surgical Intensive Care Unit (SICU) for at least 30 hours and up to 7 days-

Exclusion criteria

• Patient or legal representative unable to provide written informed consent
• Patient who is pregnant
• Patient who is currently being administered Mannitol
• Patient with history of Pulmonary Embolism (PE)
• Patient with history of thrombosis
• Patient with known hyper-coagulation
• Patient with known history of heparin hypersensitivity
• Patient with history of heparin induced thrombocytopenia
• Participation in a clinical study involving an unlicensed pharmaceutical product and/or device within the 3 months prior to enrolment in this study
• Patient with known hypersensitivity/allergy to adhesive I.V. dressings such as 3M Tegaderm film
• Patient likely to require an MRI scan during their stay in the SICU
• Patients likely to require treatment with Mannitol during time in the SICU